Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

˜The œLancet. Gastroenterology & hepatology
February 1, 2023
Cited by 221

Abstract


Related Papers

No related papers found

Powered by citation graph analysis